Final Program in it's entirety - MyGirlsBlood

Recommendations

Info

Posters, Sunday and Monday Index of Poster Presenters cont’d 08P34 Safety of Solvent Detergent Viral Inactivated Intermediate Purity Factor VIII Concentrate Shaw-Schwyzer R, Mbele B, Gillham A Haemophilia Clinic, Department of Paediatrics, Charlotte Maxeke Johannesburg Academic Hospital and University of the Witwatersrand, Johannesburg, South Africa 08P35 Preservation of Activity and Prolonged Efficacy of rFVIII after Site-Specific Modification with High Molecular Weight Hydroxyethyl Starch Sommer J1 , Sim D1 , Leong L1 , Hacket F2 , Subramanyam B1 , Haaning J1 1Bayer HealthCare Pharmaceuticals, Richmond, CA, U.S.A., 2Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany 08P36 Considerations on Long-Acting Coagulation Factors – Exemplified With FVIIa Stennicke H, Andersen H, Karpf D, Ezban M, Moess J, Soerensen B Novo Nordisk A/S, Maaloev, Denmark 08P37 Design of a Novel Long-Acting Recombinant Coagulation Factor VIII Stennicke H, Kjalke M, Moeller F, Johansen P, Oevlisen K, Karpf D Novo Nordisk A/S, Maaloev, Denmark 08P38 Preclinical Pharmacokinetic (PK) Evaluation of Glycopegylated Long Acting rFVIII Karpf DM, Kjalke M, Olsen EHN, Pelzer H, Jespersgaard C, Thim L, Bjørn SE, Agersø H, Stennicke HR Biopharmaceuticals Research Unit, Novo Nordisk A/S, Maaloev, Denmark 08P39 Patients’ Difficulties with Transfer Devices Used for Reconstitution of Factors VIII and IX Vincent I1 , Clément R2 , Hosten B1 , Taburet A1 , Rothschild C2 , Lambert T1 1 2 CHU de Bicêtre-APHP, Hôpital Necker – APHP, France 08P40 BAY 81-8973 – A New Full-Length Recombinant FVIII Product-Using Novel Manufacturing Technologies Vogel JH, Huesslein A, Goudar C, Severs J, Garger S, Bamberger T, Rastogi S, Liu S, Wang E, McDonald T Bayer Healthcare, Berkeley, California, U.S.A. 54 08P41 Prolonged Serum Half-life of a Recombinant, Albumin-Fused, Human Coagulation Factor IX (rIX-FP) in Different Animal Species Metzner H, Weimer T, Raquet E, Nolte WM, Pragst I, Zollner S, CSL Behring GmbH, Marburg, Germany 08P42 Cost Effectiveness Analysis for Octanate ® in ITI in Comparison to NovoSeven ® in the Treatment of Haemophilia Patients with Inhibitors: Russian Experience Zozulya N, Plyushch O Haematological Scientific Center RAMS, Moscow, Russia 08P43 Immune Tolerance Induction with Octanate ® in Hemophilia A Patients With Inhibitors and A Poor Prognosis: Progress Report on an Ongoing Prospective Data Collection Zozulya N1 , Plyushch O1 , Vdovin V 2 , Svirin P2 , Andreeva T3 , Benedik Dolnicar M4 , Severova T1 , Klimova N3 , Escuriola C5 , Kreuz W5 1Haematological Scientific Center RAMS, Moscow, Russia, 2 3 Izmailovskiy Children Hospital, Moscow, Russia, Saint- Petersburg city hemophilia treatment center, Saint- 4 Petersburg, Russia, National Haemophilia Center, Haematooncology Department, University Children’s hospital, Ljubljana, Slovenia, 5Johann-Wolfgang-Goethe University Hospital, Frankfurt am Main, Germany COAGULATION 09P03 Importance of Anti-Thrombin Binding in the Clearance of FVIIa After Intravenous Administration to Hemophilia Patients Agersø H1 , Pelzer H1 , Brophy D2 , Martin E2 , Ezban M1 1 2 Novo Nordisk A/S, Maaloev, Denmark, Virginia Commonwealth University, Richmond, VA, U.S.A. 09P04 Characterization and Measurement of the Non-Proteolytical Activation of rFXIII (rFXIIIa°) Andersen M1 , Kristiansen G2 , Hørlyck L2 1Biopharmaceutical Research Unit, Novo Nordisk A/S, Denmark, 2CMC Supply, Novo Nordisk A/S, Denmark 09P05 Conformational Changes of Recombinant FXIII upon Both Proteolytic and Non-Proteolytic Activation Studied by HX-MS Andersen M, Faber J Biopharmaceutical Research Unit, Novo Nordisk A/S, Denmark
Index of Poster Presenters cont’d 09P06 Prediction of Bleeding Tendencies in Hemophilia A Patients on Prophylactic Treatment Using a Novel Reaction-Diffusion Assay of Hemostasis Balandina A, Kumskova M, Kopylov K, Karamzin S, Fadeeva O, Panteleev M National Research Center for Hematology, Moscow, Russia 09P07 Evaluation of Hemodyne HAS Parameters in a Patient with Hemophilia A and An Inhibitor Who Has a Poor Clinical Response to Standard Dose rFVIIa Brophy D1 , Martin E1 , Carr M2 , Nolte M3 , Kuhn J3 , Ezban M4 1Virginia Commonwealth University Coagulation Advancement Laboratory, Richmond, VA, U.S.A., 2Novo Nordisk, Inc., Princeton, NJ, U.S.A., 3Central Virginia Center for Coagulation Disorders, Virginia Commonwealth University, Richmond, VA, U.S.A., 4Novo Nordisk A/S, Malov, Denmark 09P08 Using Global Hemostasis Laboratory Parameters to Identify rFVIIa Response Brophy D1 , Martin E1 , Ezban M2 , Hedner U2 , Carr M3 , Barrett J4 1Virginia Commonwealth University Coagulation Advancement Laboratory, Richmond, VA, U.S.A., 2Novo Nordisk A/S, Malov, Denmark, 3Novo Nordisk, Inc., Princeton, NJ, U.S.A., 4Central Virginia Center for Coagulation Disorders, Virginia Commonwealth University, Richmond, VA, U.S.A. 09P09 Inhibitor of Activated Protein C as an Adjuvant for Hemophilia Treatment Butenas S1 , Whelihan M1 , Brummel-Ziedins K1 , Rivard G2 , Mann K1 1University of Vermont, Dept. of Biochemistry, Burlington, VT, U.S.A., 2Hospital St. Justine, Montreal, QC, Canada 09P10 Corn Trypsin Inhibitor (CTI) for Thrombin Generation (TG) Assays: To Add or Not to Add Chantarangkul V, Mancuso E, Lemma L, Clerici M, Santagostino E, Tripodi A A Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy 09P11 Liver Transplantation with Mild Hemophilia A: Contribution of the Rotary Thromboelastography Desprez D1 , Faradji A2 , Cuby C3 , Mauvieux L1 , Grunebaum L1 1 2 Laboratory of Haematology, Regional Center for the Treatment of Haemophilia, 3Department of Anesthesiology, CHRU, Strasbourg, France 09P12 Pro-coagulant Activity of Laminaria Japonica Derived Fucoidan (BAX513) Depends on the Interaction with the C- Terminus of Tissue Factor Pathway Inhibitor Palige M, Dockal M, Gerstenbauer G, Redl C, Knappe S, Ehrlich H, Scheiflinger F, Baxter Innovations GmbH, Orth Donau, Austria 09P13 Quantization of Changes in VWF and FVIII Following Elective Orthopedic and Coronary Artery Bypass Graft Surgery in Normal Individuals Kahlon A1 , Grabell J1 , Tuttle A1 , Engen D2 , Hopman W3 , Lillicrap D4 , James P1 1Medicine, Kingston General Hospital, Kingston, ON, Canada, 2Anesthesiology, Kingston General Hospital, Kingston, ON, Canada, 3Community Health and Epidemiology, Kingston General Hospital, Kingston, ON, Canada, 4Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada 09P14 Combination of Recombinant Factor VIIa and Fibrinogen Corrects the Coagulopathy of Idiopathic Thrombocytopenic Purpura Larsen OH1 , Stentoft J2 , Ingerslev J1 , Sørensen B1,3 1Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Skejby, Denmark, 2Department of Haematology, Aarhus University Hospital, Aarhus, Denmark, 3Haemostasis Research Unit, St Thomas’ Hospital, London, United Kingdom 09P15 Discrepancy between One-Stage and Two-Stage Factor VIII Assays in Hemophilia A Patient: Molecular Genetic Background Pavlova A, Delev D, Brondke H, Vidovic N, Niemann B, Oldenburg J Institute for Experimental Haematology and Transfusion Medicine, Bonn, Germany 09P16 Measurement of Factor VIII – von Willebrand Factor Complex (FVIII – VWF) by Using Enzyme Immunoassay (EIA) Techniques Pelzer H, Hilden I Novo Nordisk, Maaloev, Denmark 09P17 Guidance for the Use of Different APTT Reagents on Warfarinised Patients Pickering W, Brooks S, Chowdary P, Riddell A Katherine Dormandy Haemophilia and Thrombosis Unit, Hampstead, U.K. 55 Posters, Sunday and Monday
Page 1 and 2: Hemophilia Saturday, July 10 - Wedn
Page 3 and 4: Pre-Congress Sessions cont’d 10:3
Page 5 and 6: Pre-Congress Sessions cont’d 15:0
Page 7 and 8: Congress Sessions cont’d S1.6 - M
Page 9 and 10: Congress Sessions cont’d S2.5 - M
Page 11 and 12: Congress Sessions cont’d n Long T
Page 13 and 14: Congress Sessions cont’d M2.4 - M
Page 15 and 16: Congress Sessions cont’d Tuesday,
Page 17 and 18: Congress Sessions cont’d 14:15 -
Page 19 and 20: Congress Sessions cont’d T3.4 - M
Page 21 and 22: Congress Sessions cont’d n Inhibi
Page 23 and 24: Congress Sessions cont’d W2.4 - L
Page 25 and 26: Index of Speakers cont’d Halimeh,
Page 27 and 28: Index of Poster Presenters Sunday a
Page 29 and 30: Index of Poster Presenters cont’d
Page 39: Index of Poster Presenters cont’d

Final Program in it's entirety - MyGirlsBlood

Create successful ePaper yourself

Delete template?

Save as template?